Merrimack Announces U.S. FDA Approval of ONIVYDE™ (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Merrimack Pharmaceuticals (MACK) Weakness Creates Buying Opportunity, Mizuho Securities Says
October 23, 2015 6:51 AM EDTWeakness in Merrimack Pharmaceuticals (NASDAQ: MACK) following FDA approval of ONIVYDE presents a buying opportunity, according to Eric Criscuolo of Mizuho Securities. The firm reiterated an Outperform rating and price target of $16.
Criscuolo commented, "We think the 13% decline following news of ONIVYDE approval... More
Merrimack (MACK) Onivyde Labeling Appears as Expected, Says Mizuho Securities
October 22, 2015 2:14 PM EDTMizuho Securities maintained a Buy rating on Merrimack Pharmaceuticals (NASDAQ: MACK) with a price target of $16. Shares dropped 20% after Merrimack announced FDA approval for MM-398. In the view of analyst Eric Criscuolo, the label was as expected, despite the Black Box warning for diarrhea and... More
Merrimack Pharma (MACK) Drops Lower Following ONIVYDE Approval; Will Include 'Boxed Warning'
October 22, 2015 2:10 PM EDTMerrimack (Nasdaq: MACK) shares are down over 21 percent with heavy volume Thursday afternoon after the company... More
